Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Paliperidone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 16/20 | 0.98 |
| ▸ | HTR2A known ✓ | P28223 | 15/20 | 0.98 |
| ▸ | HTR2C | P28335 | 4/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.98 |
| ▸ | HRH1 | P35367 | 3/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.98 |
| ▸ | DRD1 | P21728 | 2/20 | 0.98 |
| ▸ | DRD4 | P21917 | 2/20 | 0.98 |
| ▸ | DRD5 | P21918 | 2/20 | 0.98 |
| ▸ | HTR1D | P28221 | 2/20 | 0.98 |
| ▸ | HTR1B | P28222 | 2/20 | 0.98 |
| ▸ | HTR7 | P34969 | 2/20 | 0.98 |
| ▸ | DRD3 | P35462 | 2/20 | 0.98 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.98 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.98 |
| ▸ | HTR1A | P08908 | 7/20 | 0.74 |
| ▸ | ACHE | P22303 | 3/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Paliperidone SCHEMBL1831211 | 1.00 | DRD2 (0.98) | DRD2HTR2AHTR2CADRA1AHRH1 | |
| Paliperidone SCHEMBL20572022 | 0.99 | DRD2 (1.00) | DRD2HTR2AHTR2CADRA1AHRH1 | |
| Paliperidone SCHEMBL29409219 | 0.99 | DRD2 (1.00) | DRD2HTR2AHTR2CADRA1AHRH1 | |
| Paliperidone SCHEMBL29377584 | 0.99 | DRD2 (1.00) | DRD2HTR2AHTR2CADRA1AHRH1 | |
| Paliperidone SCHEMBL436689 | 0.99 | DRD2 (1.00) | DRD2HTR2AHTR2CADRA1AHRH1 | |
| Paliperidone SCHEMBL11899798 | 0.99 | DRD2 (1.00) | DRD2HTR2AHTR2CADRA1AHRH1 | |
| Paliperidone SCHEMBL67205 | 0.99 | DRD2 (1.00) | DRD2HTR2AHTR2CADRA1AHRH1 | |
| Paliperidone SCHEMBL1667922 | 0.98 | DRD2 (0.98) | DRD2HTR2AHTR2CADRA1AHRH1 | |
| Paliperidone SCHEMBL1443676 | 0.98 | DRD2 (0.98) | DRD2HTR2AHTR2CADRA1AHRH1 | |
| Paliperidone SCHEMBL1119094 | 0.98 | DRD2 (0.98) | DRD2HTR2AHTR2CADRA1AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2243780-A2 | Process for the purification of paliperidone | Dipharma Francis S.r.l. (IT) | 2010-10-27 | — | — | EP | claimed |
| US-20100267954-A1 | PROCESS FOR THE PURIFICATION OF PALIPERIDONE | DIPHARMA FRANCIS S.R.L. (IT) | 2010-10-21 | — | — | US | claimed |
| EP-2243780-A2 | Process for the purification of paliperidone | Dipharma Francis S.r.l. (IT) | 2010-10-27 | — | — | EP | disclosed |
| US-20100267954-A1 | PROCESS FOR THE PURIFICATION OF PALIPERIDONE | DIPHARMA FRANCIS S.R.L. (IT) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267954-A1 | PROCESS FOR THE PURIFICATION OF PALIPERIDONE | AVPR2, AVPR1A, AVPR1B | DRD2 444/4885HTR2A 224/4885HTR2C 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.